Table 2.
Patient characteristics by residential location among women with early-stage, HR+, HER2−, LN− breast cancer.
| Residential location | P value | |||
|---|---|---|---|---|
| Urban area | Large rural area | Small rural area | ||
| (N = 3859) | (N = 958) | (N = 1909) | ||
| N (Column %) | N (Column %) | N (Column%) | ||
| Age at diagnosis, years | ||||
| <50 | 612 (15.9) | 111 (11.6) | 221 (11.6) | <0.0001 a |
| 50–59 | 918 (23.8) | 212 (22.1) | 396 (20.7) | |
| 60–69 | 1218 (31.6) | 296 (30.9) | 583 (30.5) | |
| ≥70 | 1111 (28.7) | 339 (35.4) | 709 (37.2) | |
| Marital status at diagnosis | ||||
| Married/Living with partner | 2527 (65.5) | 612 (63.9) | 1277 (66.9) | 0.261b |
| Otherc/Unknown | 1332 (34.5) | 346 (36.1) | 632 (33.1) | |
| Insurance status | ||||
| Insuredd | 3503 (90.8) | 863 (90.1) | 1736 (90.9) | 0.089b |
| Any Medicaide | 216 (5.6) | 69 (7.2) | 97 (5.1) | |
| Uninsured/Unknown | 140 (3.6) | 26 (2.7) | 76 (4.0) | |
| Median household income | ||||
| <$50,000 | 688 (17.8) | 384 (40.1) | 625 (32.7) | <0.0001 a |
| $50,000-$59,999 | 726 (18.8) | 376 (39.2) | 825 (43.2) | |
| $60,000-$69,999 | 971 (25.2) | 150 (15.7) | 385 (20.2) | |
| ≥$70,000 | 1474 (38.2) | 48 (5.0) | 74 (3.9) | |
| Year of diagnosis | ||||
| 2010–2012 | 1071 (27.8) | 291 (30.4) | 565 (29.6) | 0.065a |
| 2013–2015 | 1301 (33.7) | 344 (35.9) | 638 (33.4) | |
| 2016–2018 | 1487 (38.5) | 323 (33.7) | 706 (37.0) | |
| Cancer stage | ||||
| I | 3172 (82.2) | 773 (80.7) | 1497 (78.4) | 0.003 a |
| II | 687 (17.8) | 185 (19.3) | 412 (21.6) | |
| Histology | ||||
| Ductal | 2929 (75.9) | 679 (70.9) | 1450 (76.0) | 0.033 b |
| Lobular | 459 (11.9) | 123 (12.8) | 208 (10.9) | |
| Ductal + Lobular | 147 (3.8) | 49 (5.1) | 83 (4.4) | |
| Mucinous | 110 (2.9) | 39 (4.1) | 67 (3.5) | |
| NOS/Other | 214 (5.5) | 68 (7.1) | 101 (5.2) | |
| Tumor size, cm | ||||
| 0.6–1.9 | 3007 (77.9) | 718 (75.0) | 1399 (73.3) | 0.001 a |
| 2.0–4.0 | 744 (19.3) | 207 (21.6) | 457 (23.9) | |
| >4.0 | 108 (2.8) | 33 (3.4) | 53 (2.8) | |
| Tumor grade | ||||
| Well differentiated | 1577 (40.9) | 355 (37.1) | 700 (36.7) | 0.049 b |
| Moderately differentiated | 1648 (42.7) | 437 (45.6) | 874 (45.8) | |
| Poorly differentiated/Undifferentiated | 559 (14.5) | 148 (15.4) | 303 (15.9) | |
| Unknown | 75 (1.9) | 18 (1.9) | 32 (1.6) | |
| GEP method | ||||
| Oncotype DX | 1721 (44.6) | 409 (42.7) | 784 (41.1) | 0.009 b |
| Otherf | 99 (2.6) | 12 (1.2) | 44 (2.3) | |
| Test not done | 2039 (52.8) | 537 (56.1) | 1081 (56.6) | |
Abbreviations: CM, centimeter; GEP, gene expression profiling; HER2−, human epidermal growth factor receptor 2 negative; HR+, hormone receptor-positive; LN−, lymph node negative; NOS, not otherwise specified. Bold values indicate significance at α = 0.05. aP-values are based on Cochran-Mantel-Haenszel test for trend for ordered variables. bP-values are based on Pearson chi-square test for categorical variables. c Divorced, separated, single, and widowed. d Private insurance and Medicare. e Indian Health Service. f MammaPrint, EndoPredict, BCI, and Prosigna. Bold values indicate significance at α = 0.05.